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ABSTRACT Freeze-fracture transmission electron microscopy shows signiﬁcant differences in the bilayer organization and
fraction of water within the bilayer aggregates of clinical lung surfactants, which increases from Survanta to Curosurf to Infasurf.
Albumin and serum inactivate all three clinical surfactants in vitro; addition of the nonionic polymers polyethylene glycol, dex-
tran, or hyaluronic acid also reduces inactivation in all three. Freeze-fracture transmission electron microscopy shows that poly-
ethylene glycol, hyaluronic acid, and albumin do not adsorb to the surfactant aggregates, nor do these macromolecules penetrate
the interior water compartments of the surfactant aggregates. This results in an osmotic pressure difference that dehydrates the
bilayer aggregates, causing a decrease in the bilayer spacing as shown by small angle x-ray scattering and an increase in the
ordering of the bilayers as shown by freeze-fracture electron microscopy. Small angle x-ray diffraction shows that the rela-
tionship between the bilayer spacing and the imposed osmotic pressure for Curosurf is a screened electrostatic interaction with
a Debye length consistent with the ionic strength of the solution. The variation in surface tension due to surfactant adsorption
measured by the pulsating bubble method shows that the extent of surfactant aggregate reorganization does not correlate with
the maximum or minimum surface tension achieved with or without serum in the subphase. Albumin, polymers, and their mix-
tures alter the surfactant aggregate microstructure in the same manner; hence, neither inhibition reversal due to added polymer
nor inactivation due to albumin is caused by alterations in surfactant microstructure.
INTRODUCTION
Lung surfactant is a mixture of lipids (primarily dipalmi-
toylphosphatidylcholine (DPPC)) and four lung surfactant
speciﬁc proteins (SP-A, -B, -C, and -D) that lines the interior
of the lung alveoli and acts to lower the interfacial tension in
the lungs, thereby insuring a negligible work of breathing
and uniform lung inﬂation (1,2). The absence of lung surfac-
tant due to prematurity leads to neonatal respiratory distress
syndrome (NRDS) (1,3–5). Treating NRDS with currently
available replacement surfactants has signiﬁcantly reduced
neonatal mortality in developed countries (1,3–5). However,
replacement surfactant treatment has been disappointing when
used to treat lung diseases associated with lung injury and
acute respiratory distress syndrome (ARDS) (6–8). In such
cases, surfactant loses the ability to reduce surface tension
and is said to be ‘‘inactivated’’ (4,9–11). Surfactant inactiva-
tion caused by serum leakage into alveoli is one reason treat-
ment of lung injuries with surfactant has been unsuccessful
(12,13). Several nonionic and anionic polymers have recently
been shown to enhance the ability of clinical surfactants to
resist inactivation by serum and other substances (9,14–21).
Lung function of animals with lung injury is markedly im-
proved when polymers are added to clinical surfactants used
for treatment of NRDS (9,11,16,22–24).
Surfactant inactivation is also a likely factor in the de-
velopment and progression of ARDS. ARDS has an inci-
dence of 150,000 cases per year (U.S.) and a mortality rate of
;30% (4,8,25). The pathophysiology of ARDS involves in-
jury to the alveolar-capillary barrier, lung inﬂammation, at-
electasis, surfactant dysfunction, and intrapulmonary shunting.
No speciﬁc therapy for ARDS currently exists. Although
ARDS has a more complicated pathology than the simple ab-
sence of surfactant, ARDS shares many NRDS features such
as diminished lung compliance, marked restriction of lung
volumes, and profound hypoxemia. Hence, it was hoped
ARDS might respond favorably to surfactant replacement
therapy. However, clinical trials with the most effective for-
mulations used in NRDS yield gains in ARDS patients that
are both modest and transient (4,6,7,25–28), suggesting that
ARDS involves not only a lack of functional surfactant, but
also an inactivation of the endogenous or exogenous surfac-
tant present.
In ARDS, increased concentrations of serum proteins in
the alveolar hypophase are a likely cause of inactivation; albu-
min concentrations in ARDS alveolar ﬂuid may reach 100
mg/ml, with an average concentration reported by Ishizaka
and co-workers of 25 mg/ml (29). Albumin and other serum
proteins are surface active and can quickly adsorb to the al-
veolar air-water interface to form a barrier to surfactant ad-
sorption (17,18,30). A common ﬁnding is that increased
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concentrations of surfactant and increased fractions of sur-
factant-speciﬁc proteins SP-A and SP-B reduce inactivation
(12,31–38). A more surprising ﬁnding is that hydrophilic,
nonadsorbing, nonionic, and anionic polymers added to aque-
ous mixtures of clinical surfactants (which contain SP-B and
SP-C, but not SP-A) reduce inactivation by serum, meco-
nium, albumin, and other substances both in vitro and in vivo
(9–11,14,16,22,39–41).
How polymers reverse surfactant inactivation is an open
question. Previous researchers have speculated that there is
a relationship between inhibition and surfactant microstruc-
ture (42–44) based on transmission electron microscopy of
chemically ﬁxed clinical lung surfactants. However, clinical
surfactants are .98% lipid (see Table 1), and lipid ag-
gregates are notoriously difﬁcult to ﬁx via conventional
glutaraldehyde/osmium tetroxide ﬁxation and dehydration
methods (45–48). No chemical ﬁxative reacts signiﬁcantly
with saturatured lipids such as DPPC (45), which is the dom-
inant lipid in lung surfactant. Hence, a signiﬁcant fraction
of the lipid is lost by extraction during specimen preparation,
and all information about the distribution of water in the
sample is lost (43). In comparison, rapid freezing methods
(49) followed by freeze-fracture replication can provide artifact-
free images of lipid bilayer samples in their hydrated state
with no added chemical ﬁxatives, while preserving both the
distribution of the aggregates in the original dispersion and
the microstructure and bilayer organization of the aggregates
(49–56).
Freeze-fracture transmission electron microscopy (FFTEM)
(49,50,52,54–63) of the clinical lung surfactants Survanta,
Curosurf, and Infasurf was used to determine the size and
shape distribution of the surfactant aggregates in the suspen-
sion and the organization of the bilayers within the aggre-
gates before and after exposure to albumin and polymers.
Survanta, Curosurf, and Infasurf are clinical replacement
lung surfactants in widespread use in the U.S. and Europe to
treat NRDS. Although they differ in composition of both
lipid and protein constituents, the effects of these differences
are not clear. All are effective in clinical trials, and com-
parison trials do not conclusively show advantages of one
over the other (64,65). Survanta is made from minced bovine
lung extract with the addition of DPPC, palmitic acid, and
triacylglycerol. Curosurf is an extract of whole mince of por-
cine lung tissue puriﬁed by column chromatography. Infasurf
is a chloroform-methanol extract of neonatal calf lung la-
vage. These three surfactants are primarily lipid (.98%) but
contain small fractions of the surfactant proteins SP-B and
SP-C (but not SP-A and SP-D) (66). The compositions of the
three surfactants are compared in Table 1.
FFTEM shows signiﬁcant differences in the bilayer orga-
nization of the clinical lung surfactants. The major difference
is the fraction of water within the bilayer aggregates, which
increases from Survanta to Curosurf to Infasurf. Although
each clinical surfactant has its own distinct bilayer organi-
zation, freeze-fracture images show that albumin and poly-
mers do not adsorb to any of the clinical surfactant aggregates.
Rather, both albumin and polymers act to dehydrate the sur-
factant aggregates by creating an osmotic pressure difference
between the interior of the aggregate and the exterior. The
aggregates expel any interior pockets of water and the bilayer
order is increased. There is clear evidence of fusion of smaller
aggregates to form larger aggregates, in addition to the ﬂoc-
culation observed via optical microscopy. Small angle x-ray
scattering shows that the d-spacing of Curosurf, Survanta,
and Infasurf depends on the polymer and/or albumin concen-
tration, consistent with the polymer and albumin not being
able to access the interior of the aggregates (67). The ex-
ponential dependence of the d-spacing of Curosurf on the
osmotic pressure shows that the repulsive forces between the
bilayers are due to electrostatic double-layer forces, with a
characteristic decay length determined by the ionic strength
of the solution (67–69).
Albumin, polymers, and their mixtures alter the surfactant
aggregate microstructure in the same manner; this implies
that albumin does not inactivate surfactant by alterations in
surfactant microstructure. In addition, the microstructure al-
terations of polyethylene glycol (PEG) and other polymers
do not themselves reverse surfactant inactivation. This has
been shown by comparing the effects of 5 wt % 10 kDa PEG
with 0.25 wt % 250 kDa hyaluronic acid (HA) on surfactant
microstructure and surfactant inactivation. Pulsating bubble
surfactometer (PBS) measurements show that these polymer
concentrations are sufﬁcient to reverse inactivation of Survanta,
Curosurf, and Infasurf; the lower HA concentration actually
provides more complete inactivation reversal than does the
TABLE 1 Consensus lipid composition (%, g/g of total lipid)
and protein concentration (% phospholipid, g/g)
of clinical surfactants
Native
Surfactant Curosurf Infasurf Survanta
PC % (w/w) 70–85 67–74 70–74 79–87
DPPC (%PC) 36–59 50–56 41–61 45–75
LPC 0.5 ,1 1
Sphingomyelin 2 8.1 2 4.8
Cholesterol 5 0 5 0
PI 4–7 3.3 ;2 0.5
PS 5 ;2
PE 3 4.5 3 2.2
PG 7–10 1.2 6 3.2
PA 6–14
Unknown 4.3
SP-A 4 0 0 0
SP-B 1 0.3 0.4–0.9 0.04–0.13
SP-C 1 0.7 0.6 0.9–1.65
SP-D 4 0 0 0
PC, phosphatidylcholine; DPPC, dipalmitoylphosphatidylcholine; LPC,
lysophosphatidyl choline; PI, phosphatidylinositol; PS, phosphatidylserine;
PE, phosphatidylethanolamine; PG, phosphatidylglycerol. Range of reported
averages are taken from the following sources: (Curosurf, Package inserts
from Chiesi Farmaceutici, Parma, Italy; ONY, New York; and Survanta,
Ross Labs, Ohio) (33,64,66,104,105).
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higher PEG concentration. As osmotic pressure, Pos, is pro-
portional to the number of polymers in a dilute solution,
Pos  ðwp=MÞRT, (Pos in dynes/cm2, wp is the weight
fraction polymer,M is the molar mass in g/mole, R is the gas
constant, 8.314 3 107 g-cm2/(s2-mole-K), and T is the abso-
lute temperature (67)), the PEG solution has an osmotic pres-
sure more than 100 times higher than the HA solution. FFTEM
shows that PEG signiﬁcantly alters the bilayer organization
of the surfactant aggregates, whereas HA does not. In ad-
dition, FFTEM images show that Survanta aggregates are
changed minimally, whereas Infasurf and Curosurf undergo
extensive rearrangements with 5 wt % PEG; however, all three
surfactants show inactivation reversal with 5 wt % PEG.
Hence, inactivation reversal does not correlate with the ex-
tent of surfactant aggregate disruption caused by polymers.
MATERIALS AND METHODS
Infasurf (Forest Pharmaceuticals, St. Louis, MO) was purchased from the
hospital pharmacy at University of California, San Francisco. Survanta (Abbott
Laboratories, Columbus, OH) was obtained from the San Francisco General
Hospital nursery. Curosurf was purchased from Dey Laboratories (Napa,
CA). Curosurf, Infasurf, and Survanta are suspensions of bilayer aggregates
in 0.15M NaCl at total concentrations of 80, 35, and 25 mg/ml, respectively,
and are refrigerated for storage. Before use, the surfactant suspensions are
equilibrated at room temperature and swirled gently to obtain a homoge-
neous suspension. The suspensions are diluted as needed with freshly
prepared saline buffer (150 mM NaCl (EM Science; Gibbstown, NJ), 2 mM
CaCl2 (Acros Organics, Geel, Belgium; Fisher Scientiﬁc, Pittsburgh, PA),
and 0.2 mM NaHCO3 (EM Science) in deionized water and adjusted to
pH ¼ 7.0) to the desired concentration. The consensus compositions of the
clinical surfactants and human lung surfactant are given in Table 1.
Polyethylene glycol (PEG; 10 kDa) and bovine serum albumin were
purchased from Sigma (St. Louis, MO). HA (250 kDa) was a gift from
GlycoMed Research, (New York, NY). Samples containing polymer and/or
albumin were prepared by mixing stock solutions of polymer and/or albumin
with concentrated surfactant suspensions, then diluting with saline buffer to
the desired concentration. The samples are swirled gently and equilibrated
overnight in the refrigerator. Samples are allowed to equilibrate at room tem-
perature before use.
Native surfactant was obtained by saline bronchoalveolar lavage of calf
lung. The recovered lavage ﬂuid was centrifuged at 500 3 g for 10 min
followed by further centrifugation in distilled water at 17,0003 g for 2 h at
10C. The pellet obtained was lyophilized and stored at 4C before use. The
concentration of native calf surfactant was determined by lipid phosphorus
after Bligh-Dyer extraction (70). Serum was obtained from normal adult
laboratory volunteers and also kept frozen at 80C. Protein content of sera
was 6.8 g/dl.
Surface activity measurement
Native surfactant was resuspended in 0.9% NaCl at a concentration of 1.0
mg/ml. The therapeutic surfactants were diluted with 0.9% saline to 1.25
mg/ml. Dry polymers (PEG, HA, or dextran) were added to surfactants and
mixed by vortex for ;60 s at room temperature to a ﬁnal concentration of
5% (w/v) (PEG and dextran) or 0.25% (HA). Samples were mixed again by
vortex before testing. Serum was used as a nonspeciﬁc inhibitor of surfactant
in these experiments. Five microliters of serum/ml of surfactant suspension
were used for inactivation of Curosurf and Infasurf. A total of 10 ml/ml of
serum was used to inactivate Survanta and native surfactant. These serum
concentrations relative to surfactants were selected by requiring the
minimum surface tension to be above 14 mN/m after cycling for 5 min in
the absence of polymer.
Surface activities were measured in a modiﬁed PBS (Electronetics,
Buffalo, NY), using a technique to prevent the wetting of the capillary tube
(71). Twenty seconds after formation of an initial static bubble, the micro-
bubble was inﬂated and deﬂated at 20 cycles per min with a radius varying
between 0.4 mm and 0.55 mm. The temperature of the sample chamber was
maintained at 37C. Minimum and maximum surface tensions were re-
corded at the 10th cycle (after 30 s of cycling) and after 5 min. The surface
tension was calculated by the Laplace equation, P ¼ 2g/r, where g is the
surface tension, P the inﬂating pressure, and r the bubble radius. We deﬁned
DA10 as the change in bubble size necessary for surface tension to fall to 10
mN/m. That is, DA10 ¼ [(maximum surface area (SA)  SA @10 mN/m)/
maximum SA]3 100. If the surface tension did not reach 10 mN/m, then we
assigned a value of 47% for DA10, that being the maximum difference in
surface area between the largest and smallest bubble during cycling. The
data are presented as means6 SE. Group differences were analyzed by one
way analysis of variance (ANOVA). Tukey or Kruskal-Wallis tests were
used to correct for multiple comparisons and a corrected p , 0.05 was
considered signiﬁcant.
Small angle x-ray diffraction
Small angle x-ray scattering experiments were performed on a custom-built
instrument with an 18-kWRigaku rotating anode source (CuKa, l¼ 1.54 A˚,
Rigaku, The Woodlands, TX) and 2-d area detector. The instrument is
optimized for very small angle work (5–60 nm) and has an Osmic Confocal
Maxﬂux double focusing multilayer mirror (Osmic, Auburn Hills, MI), an
11-cm Bruker HI-STAR multiwire area detector (Bruker, Billerica, MA),
and a 1.5-m sample to detector distance. The full width at half-maximum
was ,;0.005 A˚1. In all experiments, samples were loaded into 1.5-mm
borosilicate glass capillaries (Charles Supper, Natick, MA) and ﬂame sealed.
Temperature control was via circulating heated or cooled ﬂuid through an
aluminum sample holder block, monitored by a thermistor located adjacent
to the capillary (72).
Freeze-fracture electron microscopy
Freeze-fracture samples were prepared by ﬁrst depositing a ﬁlm of sample
liquid ;100 microns thick between two copper planchettes. The samples
were frozen by plunging the sample into a liquid propane/liquid ethane bath
cooled by liquid nitrogen. The frozen sample was transferred under liquid
nitrogen to the sample block of an RFD-9010 (RMC, Tucson, AZ, dis-
continued) freeze-fracture device. After temperature (170C) and pressure
(,107 torr) equilibration, the sample was fractured and the two resulting
surfaces were replicated with ;1.5 nm platinum deposited at a 45 angle,
followed by;15 nm of carbon deposited normal to the surface. The copper
planchettes were dissolved in chromerge (a mixture of chromic acid, sulfuric
acid, and water), and then the replicas were washed in water and allowed to
stand in ethanol several days to dissolve any remaining surfactant. The
replicas were collected on formvar-coated TEM grids (Ted Pella, Redding,
CA) (49). A Gatan charge-coupled device camera (Gatan, Pleasanton, CA)
was used to record digital brightﬁeld images using an FEI Technai
(Eindhoven, Netherlands) transmission electron microscope at 100 KeV.
RESULTS AND DISCUSSION
As received, the Curosurf suspension consisted of multi-
lamellar aggregates with a broad size distribution ranging
from 100 nm to 3 mm (Fig. 1, A and B). The larger aggregates
were invariably multilamellar but with poorly organized
bilayer arrangements with ‘‘pockets’’ of water within the
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aggregate. The bilayers within the aggregates were not well
correlated, consistent with the small angle x-ray diffraction
showing broad reﬂections at these conditions (see Fig. 10 A).
Diluting the suspension to 10 mg/ml with saline buffer (Fig.
1, C–F) did not change the appearance of the aggregates or
the d-spacing. The aggregate shapes varied from spheroidal
to dumbbell shaped (Fig. 1, E and F). The interior of the
aggregates were not as well organized as typical phospha-
tidylcholine aggregates in water (46,50). No changes were
observed when any of the clinical surfactants was diluted
with saline buffer, consistent with the general behavior and
microstructure of multilamellar liposomes (46,50,63).
Infasurf showed distinctly different structures than Curosurf.
Infasurf consists of relatively monodisperse, unilamellar ves-
icles of diameter 250 nm 6 100 nm (Fig. 2 A), a substantial
fraction of which are trapped within one or more bilayers
to form particles ranging from 0.5 to 4 mm (Fig. 2, B–F).
There is a signiﬁcant amount of water within each aggregate,
distributed throughout the void spaces between and within
the small vesicles inside each larger aggregate. Structurally,
the Infasurf particles are similar to ‘‘vesosomes’’, a drug de-
livery vehicle made by entrapping small vesicles within a
larger vesicle (54,73,74). Previous work on vesosomes has
shown that cholesterol can lead to this type of vesicle within
vesicle structure (73,74); Infasurf is the only clinical surfac-
tant with a signiﬁcant fraction of cholesterol (Table 1).
Survanta had the largest aggregates, which consisted of
well-organized stacks of bilayer sheets (Fig. 3, A–C) that
FIGURE 1 FFTEM images of Curosurf at a con-
centration of 80 mg/ml (A, B) and 10 mg/ml (C–F),
quenched from room temperature. (A, B) Multilamellar
aggregates with a broad size distribution. The smallest
spherical particles may be unilamellar vesicles. (C–E)
Multilamellar aggregates often had some void space
between bilayers and ‘‘pockets’’ of water within the ag-
gregate. This is consistent with the small angle x-ray
scattering that showed broad reﬂections indicative
of poor correlations between the bilayers. (F) Multi-
lamellar dumbbell-shaped aggregate.
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extended over microns. Individual aggregates were too large
to obtain an accurate size from FFTEM (See optical images
in Fig. 4). In addition to the large bilayer aggregates, a few
small unilamellar vesicles of 50–300 nm were found (Fig.
3, B and D). These aggregates were similar to pure DPPC
aggregates in microstructure (62,75,76); Survanta has the
highest concentration of DPPC of any of the clinical sur-
factants (Table 1). No water pockets or voids were observed
within the aggregates, as with Curosurf and Infasurf.
Optical phase contrast microscopy of the diluted Survanta
suspension showed aggregate sizes ranging from 5 to 60 mm.
There were a variety of aggregate shapes, from large open
bilayer fragments (Fig. 4 A, arrow), loosely packed bilayer
aggregates (Fig. 4, B–D), and more tightly packed multilayer
aggregates (Fig. 4, B and C).
Albumin effects on surfactant microstructure
Serum is known to inactivate lung surfactants in vitro, and
serum protein levels are elevated in ARDS patients
(12,13,29,31). Albumin is the most common surface active
protein in serum (77) and was used in the freeze-fracture and
small angle x-ray experiments to quantify the protein con-
centration and osmotic pressure. Albumin and many other
serum proteins found in the bronchial ﬂuid of ARDS pa-
tients are surface active and have a surface tension that is a
FIGURE 2 FFTEM images of Infasurf at a concen-
tration of 10 mg/ml, quenched from room temperature.
(A) Small, fairly monodisperse unilamellar vesicles with
average diameter of 250 nm 6 100 nm. (B) Densely
packed small vesicles within another bilayer membrane,
indicated by the bumpy surface, where the densely
packed vesicles push against the outer membrane. Small
vesicles appear to be loosely bound to the larger ag-
gregate. (C–F) Cross-fractured Infasurf aggregates with
densely packed interior vesicles and large water pock-
ets. The diameters range from 0.5 to 4 mm. The struc-
tures are similar to vesosomes, a vesicle in vesicle drug
delivery vehicle (73,74).
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logarithmic function of protein concentration up to a satura-
tion concentration, which is ;1 mg/ml for albumin (30,77).
Because of its modest molecular weight, albumin is easily
leaked into airspaces during lung injury when endothelial and
epithelial damage occurs. Albumin concentrations in ARDS
alveolar ﬂuid may reach 100 mg/ml, with an average con-
centration reported by Ishizaka and co-workers of 25 mg/ml
(29). An added beneﬁt for these experiments on rapid sur-
factant inactivation is that albumin has little chemical re-
activity with surfactant, unlike other inﬂammatory proteins
(e.g., phospholipases) that make in vitro experiments at times
difﬁcult to interpret. The measured minimum surface ten-
sion, gmin, for human serum and many of the proteins present
in serum, such as albumin, hemoglobin, thrombin, IgG, and
IgM, is within a rather narrow range of 45–50 mN/m (77),
independent of the details of the protein structure, molecular
weight, or function (77). In vitro, albumin concentrations
greater than the saturation concentration of 1 mg/ml inacti-
vate lung surfactant (30,78).
However, Fig. 5 shows that albumin concentrations 0.5–5
mg/ml have little effect on the microstructure of Curosurf.
Albumin does not appear to adsorb or interact signiﬁcantly
with the Curosurf aggregates over the range of concentration
that inactivates surfactant. Individual albumin molecules ad-
sorbed to the interface would appear as distinct 5–10-nm-high
bumps or pits on the bilayer surfaces. This is consistent with
the small angle x-ray scattering that shows that the primary
effect of albumin is as an osmotic agent that cannot penetrate
the bilayers of the aggregate (see Fig. 9). Fig. 6 shows that
Infasurf and Survanta also are not altered in 2 mg/ml albu-
min. The osmotic pressure of a 2 mg/ml albumin solution is
;103 dynes/cm2, which is not sufﬁcient to alter the spacing
of the bilayers (see Fig. 9). Although Infasurf, Curosurf, and
Survanta have quite different compositions and microstruc-
tures, albumin does not adsorb to or alter the lamellar orga-
nization of any of the clinical surfactants at concentrations at
which surfactant is inactivated.
Hydrophilic, nonadsorbing polymers added to aqueous
mixtures of clinical surfactants (which contain SP-B and
SP-C, but not SP-A) reduce rapid inactivation in vitro and
in vivo (Table 2). Animal studies have shown that these
polymers can reverse clinical surfactant inactivation (9–
11,14,16,22,39–41). Fig. 7 (18) shows the dramatic effects
of 5 wt % 10 kDa PEG on the dispersions of clinical sur-
factants. The added polymer leads to a rapid ﬂocculation of
each of the surfactant dispersions. The ﬂocculation is revers-
ible; gentle agitation can break up the ﬂocs, which can then
reform over the course of minutes. This is typical for any
dispersion when a nonadsorbing polymer is added (18,79).
Freeze-fracture TEM images of individual Curosurf aggre-
gates showed signiﬁcant differences with the addition of
PEG (Fig. 8). Although there was little change in the average
FIGURE 3 FFTEM images of Survanta at a con-
centration of 10 mg/ml (A, B) and 2 mg/ml (C, D),
quenched from room temperature. (A, C) Most aggre-
gates were too large to be imaged as individual par-
ticles in TEM. Here we shod the multilamellar stacks
of well-ordered bilayers within the larger aggregates.
There are no water pockets within the Survanta par-
ticles. (B, D) The only other structures observed are
small vesicles that range from 50 to 300 nm in di-
ameter.
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aggregate size, the organization of the bilayers within the
aggregates was altered: the average bilayer spacing decreased
and there were no longer any void spaces within the aggre-
gates. The bilayers are much better organized after exposure
to PEG (see Figs. 9 and 10).
Small angle x-ray scattering conﬁrmed that the added
polymer acted to dehydrate the aggregates and decrease the
d-spacing between the bilayers (Fig. 9). Consistent with ear-
lier results (67), macromolecules such as 10 kDa PEG or
albumin cannot enter the aqueous spaces within the surfac-
tant aggregate. This generates a concentration difference be-
tween the inside and outside of the aggregate, which in turn
generates an osmotic pressure difference that causes dehy-
dration of the aggregate. With no albumin or polymers in the
solution, Curosurf has a bilayer d-spacing of;11 nm, which
decreases to ;6 nm at the highest applied osmotic pressure
difference. From Fig. 9, there is an exponential decrease in
the d-spacing of the surfactant bilayers with osmotic pressure
difference (proportional to the polymer concentration) (67).
The applied osmotic pressure difference is balanced against
the interbilayer repulsion, which determines the d-spacing.
The characteristic decay length of the line ﬁtted to the data
0.726 .02 nm (67). The characteristic length for electrostatic
double-layer repulsion between the bilayers is the Debye
length, K. K is inversely proportional to the square root of the
ionic strength of the solution (80): K ¼ ð:304= ﬃﬃIp Þ nm and
I ¼ 1=2+riZ2i  :154mol=liter. ri is the molar concentra-
tion of each ion, and Zi is the charge on that ion. This gives
K ¼ .77 nm for the buffer used in these experiments. Any
additional counterions from the anionic lipids in the sur-
factant (or albumin) increase the ionic strength and further
reduces K. The agreement between the experimental decay
length and the Debye length of the solution is good and is
typical for ﬂuid bilayers with a signiﬁcant fraction of charged
lipids (see Table 1) (67,69).
Also plotted in Fig. 9 is the effect of increasing albumin
concentrations on the d-spacing, as well as mixtures of al-
bumin and polymer. When the albumin concentration is ex-
pressed as the equivalent osmotic pressure, the d-spacings of
the Curosurf aggregates in albumin or albumin plus polymer
fall on the same line as for polymer alone. Albumin also acts
as an osmotic agent and cannot enter into the aqueous spaces
of the surfactant aggregates (Fig. 10). For the 2 mg/ml albu-
min that inactivates surfactant, the osmotic pressure (,103
dynes/cm2) is not sufﬁcient to alter the d-spacing of Curosurf,
which is why the freeze-fracture images of Curosurf with
2 mg/ml albumin are unchanged from Curosurf in buffer
whereas higher albumin concentrations act similarly to higher
PEG concentrations.
Adding 5 wt % 10 kDa PEG to Infasurf also led to de-
hydration of the surfactant aggregates and a decrease in the
bilayer spacing. Fig. 11 shows that the PEG caused the
FIGURE 4 Optical phase contrast microscopy im-
ages of Survanta at a concentration of 1 mg/ml. Ag-
gregates size range from 5 up to 60 mm and show large
open bilayer structures (A, arrow), low density bilayer
aggregates (B, D), and higher density multilayer aggre-
gates (B, C).
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Infasurf vesicles to aggregate and fuse. Instead of the vesicle
within vesicle structure common when there was no PEG
(Fig. 2), the Infasurf aggregates are much more compact with
concentric, onion-like bilayer structures. The void spaces and
water pockets were removed and the interior compartments
have fused. Small angle x-ray diffraction showed that the
d-spacing of the Infasurf bilayers decreased from ;7.8 nm
with no PEG to ;7.1 nm with 5 wt % PEG. The diffraction
peaks changed from weak and diffuse with no PEG (typical
of poorly correlated bilayers (as in Fig. 2)) to strong, sharp
peaks (not shown) indicative of well-correlated bilayers con-
sistent with Fig. 11. The amount of water within each ag-
gregate was signiﬁcantly reduced. Survanta, which consisted
of compact bilayers with no void spaces, did not show any
overall morphological effects caused by adding PEG at 5 wt
% (not shown). However, the bilayer spacing also decreased
as measured by small angle x-ray from ;7.8 nm with no
PEG to ;7.5 nm with 5 wt % PEG. At 5 wt % PEG, the
bilayer spacing of Curosurf is ;7.5 nm. All of the clinical
surfactants had similar bilayer arrangements in 5 wt % PEG.
Fig. 12 shows the effects of 0.25 wt % 250 kDa HA on the
microstructure of Infasurf. There is little difference between
the Infasurf aggregates with or without HA (compare Fig. 12
to Fig. 2). This is not surprising as the osmotic pressure of the
HA solution is only ;103 dynes/cm2, compared to the 105.1
dynes/cm2 of the 5 wt % 10 kDa PEG solution. HA, like
PEG, does not appear to adsorb to the Infasurf bilayers.
Surface activity
Table 2 shows surface activities of the four surfactants
without serum inactivation measured with the PBS. All the
surfactants reached a minimum surface tension below 4 mN/
m after 5 min of cycling with or without added polymer.
Added polymer did decrease the change in bubble size
necessary for surface tension to fall to 10 mN/m, DA10. DA10
decreased by 38% when PEG or HA was added to Survanta
and by 36% when dextran or HA was added to Curosurf.
This suggests increased surfactant adsorption to the bubble
in the presence of polymers (17,18). The maximum surface
tensions were unaffected by addition of polymer.
Table 3 shows the surface activities of the four surfactants
after serum inactivation in the presence and absence of PEG,
HA, or dextran. Before adding the polymers, none of the
clinical surfactants or native surfactant could reach a mini-
mum surface tension of 10 mN/m on the 10th cycle or even
after 5 min of cycling. Serum clearly inactivates all of the
clinical surfactants as well as native surfactant under these
conditions. After 5 min of cycling, Survanta, Curosurf, and
Infasurf all had minimum surface tensions that were lower
than control values when PEG, HA, or dextran was added.
However, native surfactant only showed a reduction in mini-
mum surface tension when HA was added. Maximum sur-
face tensions were higher for the clinical surfactants than for
native surfactant (37–41 vs. 26 mN/m) and were unaffected
FIGURE 5 FFTEM images of 10 mg/ml Curosurf
with bovine serum albumin (BSA) at different concen-
trations, quenched from room temperature. (A) cBSA ¼
0.5 mg/ml. (B) cBSA ¼ 1 mg/ml. (C) cBSA ¼ 2 mg/ml.
(D) cBSA ¼ 5 mg/ml. Adding BSA at different con-
centrations did not change the aggregate structures in
comparison to Fig. 1. The microstructure of the aggre-
gates was multilamellar with interior voids and water
pockets and poorly correlated bilayers as in Fig. 1. The
size distribution of the aggregates was unchanged and
ranged 0.5–3 microns.
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by addition of serum. PEG decreased the maximum surface
tension for Survanta, Curosurf, and Infasurf, and dextran de-
creased the maximal surface tension for Curosurf and native
surfactant.
By deﬁnition, none of the four surfactants had a DA10 ,
47 after addition of serum as the minimum surface tension
was .10 mN/m. When PEG, HA, or dextran was added to
the clinical surfactants, DA10 decreased, although generally
not to the level for surfactants with no serum (Table 2). Ef-
fects on DA10 were most evident with HA for all surfactants
except Infasurf. However, all of the polymers led to im-
proved performance of the clinical surfactants and at least
partial reversal of inactivation. There were small differences
between the polymer/clinical surfactant combinations; how-
ever, the surfactant/polymer ratios examined were not opti-
mized, so these small variations are not unexpected.
DISCUSSION
FFTEM shows that the composition differences between
these clinical surfactants (Table 1) are manifested in the
microstructure and bilayer organization of the dispersed sur-
factants. Survanta has the largest aggregates with the best-
ordered bilayers: there are no water pockets or voids within
TABLE 2 Data for four surfactants are shown with and without added polymer
Survanta Curosurf
PEG dextran HA PEG dextran HA
STmin (mN/m) 10
th cycle 4 6 0.5 2 6 1* 3 6 0.7 1 6 0* 12 6 1 13 6 2 3 6 1* 8 6 0.4
STmin (mN/m) 5 min 4 6 0.6 1 6 1* 2 6 0.7* 1 6 0.2* 4 6 1 3 6 1 0.4 6 0.4* 0.2 6 0.2*
A10 (% area reduction) 21 6 3 13 6 1* 19 6 2 13 6 1* 22 6 2 18 6 2 14 6 1* 14 6 2*
Infasurf Native surfactant
PEG dextran HA PEG dextran HA
STmin (mN/m) 10
th cycle 15 6 1 13 6 1 9 6 2* 10 6 2 17 6 1 12 6 1* 9 6 2 9 6 1*
STmin (mN/m) 5 min 5 6 1 6 6 1 3 6 2 2 6 1* 2 6 0.7 6 6 2 3 6 1 0 6 0*
A10 (% area reduction) 28 6 1 24 6 1 22 6 1* 18 6 3* 22 6 2 16 6 2 18 6 2 14 6 2*
STmin, minimal surface tension during cycling. Area reduction (DA10) after 5 min of cycling without serum inactivation.
*p , 0.05, estimated by ANOVA corrected for multiple comparisons.
FIGURE 6 FFTEM images of Infasurf (A, B) and
Survanta (C, D) at 10 mg/ml after adding bovine serum
albumin (BSA) at a concentration of 2 mg/ml, quenched
from room temperature. Adding BSA did not change
the aggregate structures of either formulation. (A, B)
Infasurf showed small, fairly monodisperse vesicles
and densely packed vesicle aggregates. The bilayer sur-
faces were smooth, indicating no adsorption or pertur-
bation by the albumin. (C,D) Survanta primarily formed
stacks of bilayer sheets and only a few small vesi-
cles with no evidence of albumin adsorption (see Figs.
2 and 3).
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the aggregates. This is to be expected from the large fraction
of saturated DPPC and palmitic acid in Survanta (Table 1),
these bilayers are in the semicrystalline gel, Lb phase at
room, and body temperature (62,76,81,82). Such gel phase
bilayers pack better than more ﬂuid, La phase bilayers, as the
bilayers undergo smaller thermal ﬂuctuations due to their
increased rigidity (83–88).
Curosurf is intermediate in the fraction of saturated lipids,
leading to more poorly ordered bilayers and water pockets
within the aggregates. Small angle x-ray scattering shows
that the bilayer spacing is determined by repulsive electro-
static double layer forces and the d-spacing is consistent with
ﬂuid La phase bilayers with a strong repulsive electrostatic
interaction and large thermal ﬂuctuations (67,69). The bilayer
spacing is rather poorly deﬁned and the bilayers are not well
ordered.
As received, Infasurf has the most unusual aggregates,
consisting of small unilamellar vesicles trapped within an
enclosing bilayer membrane. The interior of the particles is
full of water pockets and voids. This structure is not typical
of simple lipid dispersions and may be due to the fact that
Infasurf is the only one of these clinical surfactants to contain
cholesterol (74).
The primary effect of albumin and polymer on the mi-
crostructure of the clinical lung surfactants is via osmotic
pressure. Many macromolecules cannot penetrate bilayer ag-
gregates, resulting in a concentration difference between the
interior aqueous compartments of the surfactant aggregate
FIGURE 7 Optical phase contrast microscopy im-
ages of Curosurf (A, B), Infasurf (C, D), and Survanta
(E, F) before and after 5 wt% 10 kDa PEG addition.
(A, C, E) Without PEG, all of the clinical surfactants
consisted of dispersed, small aggregates (B, D, F).
Adding PEG induced ﬂocculation of the small aggre-
gates and formed large agglomerations of up to 100
mm. These large ﬂocs could be redispersed by gentle
agitation, indicating that the forces holding the ﬂocs
together were reversible, which is typical for depletion
attraction (18,79).
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and the bulk solution. Such a concentration difference gener-
ates an osmotic pressure difference proportional to the polymer/
albumin concentration and inversely proportional to the poly-
mer molecular weight. At concentrations sufﬁcient to inhibit
surfactant, freeze-fracture TEM images show that albumin
does not signiﬁcantly alter the structure of any of the clinical
surfactants. Hence, it is clear that microstructural changes to
the surfactant in the suspension are not responsible for sur-
factant inactivation in vitro. The osmotic pressure of the low
molecular weight PEG solutions capable of reversing in-
activation are sufﬁciently high that the microstructure of
Curosurf and Infasurf are signiﬁcantly altered. The PEG (or
high albumin concentrations) dehydrates the aggregates,
leading to a removal of the interior water pockets and voids
in the aggregates and a decrease in the bilayer spacing. The
morphology of Survanta, which has relatively well-ordered
bilayers, is not affected by PEG, although the bilayer spacing
does decrease as in Curosurf and Infasurf. For 5 wt % PEG,
all three clinical surfactants are onion-like, with well-ordered
bilayers; the d-spacings range 7.1–7. 5 nm. In contrast, the
lower concentrations of the higher molecular weight HA that
reverse inactivation do not alter the microstructure of even
Infasurf, the surfactant most affected by PEG. The osmotic
pressure of the HA solution is simply too low to alter the
microstructure.
However, PBS experiments showed that all three clinical
surfactants were inactivated by serum, and adding any one of
the polymers tested reversed inactivation. There were small
variations between the pairs of surfactant/polymer in the
minimum surface tension and the area changes required to
reach a low surface tension that were likely due to the lack of
optimization of conditions for each pair. However, there was
no correlation between the microstructure changes in the
surfactant aggregates and the extent of inhibition reversal.
HA, which did not alter the surfactant microstructure, was, in
general, more effective at inhibition reversal than PEG or
dextran. The lack of correlation between surfactant inacti-
vation or reversal and surfactant microstructure alteration
refutes the hypothesis that inactivation or inactivation
reversal is due to changes in the bilayer organization.
Although the osmotic forces can be sufﬁcient to alter the
bilayer organization, the differences in energy are likely to be
insufﬁcient to inﬂuence the amount of surfactant at the in-
terface. The change in the chemical potential, Dm, per mol-
ecule in the bilayer due to the applied osmotic pressure, Pos,
is given by the work done by the osmotic pressure in chang-
ing the volume of the surfactant (67):
Dm ¼ PosDV
DV is the change in volume due to the change in osmotic
pressure. From Fig. 9, the maximum change in d-spacing is
;5 nm for an applied osmotic pressure of 106 dynes/cm2.
Assuming an average area per molecule of 0.5 nm2 for lipids,
the change in volume per molecule due to the osmotic
FIGURE 8 FFTEM images of 10 mg/ml Curosurf
after adding 5 wt % 10 kDa PEG at different con-
centrations. (A) cPEG¼ 1 wt %. (B) cPEG¼ 5 wt %. (C)
cPEG¼ 10 wt %. (D) cPEG¼ 20 wt %. As in the optical
images (Fig. 7), the PEG caused ﬂocculation of the
surfactant aggregates. In addition, there appeared to be
fusion of the smaller vesicles and the bilayers became
better ordered within the aggregates. The pockets of
water and void spaces were eliminated at the higher
PEG fractions. This is consistent with the PEG acting
as a nonpenetrating osmotic agent that dehydrates the
surfactant aggregates.
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pressure is;1.25 nm3 (there are two molecules per bilayer).
As a result, the net change in chemical potential is 1.25 3
1015 ergs/molecule, which should be compared to the
thermal energy, kBT, of ;4 3 10
14 ergs/molecule. Hence,
the osmotic pressure alters the chemical potential ,.06 kBT,
so the change in conversion between bilayer and monolayer,
which likely depends on differences in the chemical potential
of individual surfactant molecules in monolayers or bilayers,
should not be affected.
PEG, dextrans, and HA are all approved in various forms
for internal use in humans by the Federal Drug Administra-
tion. PEG is a linear or branched neutral polymer with the
general formula H(OCH2CH2)nOH. When used in high con-
centrations it acts as a cellular fusagen (89). This is con-
sistent with the effects we observe on both Curosurf and
Infasurf bilayer aggregates at high PEG concentrations. The
osmotic pressure of the PEG is sufﬁcient to cause fusion and
reorganization of the bilayers in the aggregates, along with a
decrease in the bilayer spacing.
HA differs from PEG and dextran in several respects. HA
is an ionic, nonsulfated polymer of N-acetyl-glucosamine
linked b-1, 4 to glucuronic acid which is linked b-1, 3 to
N-acetylglucosamine. HA serves many different roles in the
body, depending largely on its molecular weight. For ex-
ample, high molecular weight HA aids in the lubrication of
joints and comprises ﬁller material for the vitreous humor of
the eye and the umbilical cord of the fetus. Low molecular
weight forms are agonists for intracellular processes as di-
verse as inﬂammation or normal differentiation (90). In the
lungs, HA and other glycosaminoglycans are secreted by
alveolar epithelial cells (91,92). HA in normal rat broncho-
alveolar lavage has a molecular mass of ;220 kDa (93),
much lower than that of the lung interstitium (;3000 kDa)
(94). In alveolar subphase ﬂuid, HA is reported to have
a concentration of ;4000 mg/L based on estimates from
bronchoalveolar lavage (93). These may be underestimates
because of inefﬁciency of removal of protein-bound HA and
because of uncertainty in estimating subphase volumes. Sev-
eral beneﬁcial effects have been reported for HA in the air
spaces or airways. Aerosolization of HA (;100 kDa) into
the lungs does not cause histological inﬂammation, and its
use decreases risk of elastase-induced or smoking-induced
experimental emphysema (95,96). Forteza and co-workers
ﬁnd that endogenous HA stimulates airway ciliary action and
may serve to enhance airway defenses (97). Nitzan and co-
workers report that HA decreases phospholipase degradation
of liposomes (98). Additional proposed beneﬁcial effects
relate to cystic ﬁbrosis, asthma, or injury from bleomycin or
tobacco smoke (90).
As PEG, dextran, HA, etc. have little in common chem-
ically but all reverse inhibition in all clinical surfactants, a
physical explanation for surfactant inhibition reversal seems
more likely than one that depends on speciﬁc chemical in-
teractions between polymers and surfactants. One possibility
recently advanced is that serum inactivation is due to com-
petitive adsorption of surface-active proteins at the air-water
interface and that polymer-induced inactivation reversal is
FIGURE 9 Bilayer d-spacing measured by small angle x-ray scattering
from dispersions of Curosurf, Curosurf plus albumin, and Curosurf plus
albumin and PEG polymer as a function of the osmotic pressure of polymer
or polymer plus albumin. For osmotic pressures.103 dynes/cm2, the d-spacing
decreases exponentially with increasing osmotic pressure with a decay
length of 0.72 nm, which is nearly identical to the calculated Debye length of
the solvent. The albumin and polymer act primarily as osmotic agents that
dehydrate the bilayers, as in the TEM images. This conﬁrms that albumin
and polymer do not adsorb to or penetrate the surfactant aggregates.
FIGURE 10 Small angle x-ray diffraction of Curosurf
(A) as received and (B) with 50.1 mg/ml bovine serum al-
bumin, which is equivalent to an osmotic pressure of 104.25
dynes/cm2. As received, the single bilayer reﬂection from
Curosurf is broad, indicative of poorly organized bilayers
as in Fig. 8 A. After dehydration and rearrangement due to
the osmotic pressure induced by the added BSA, the bi-
layer spacing has decreased and the order of the bilayers
has increased, as shown by the much sharper reﬂections
along with the appearance of the second reﬂection.
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due to elimination of the energy barrier to adsorption via the
so-called ‘‘depletion attraction’’ (17,18,78). In a suspension-
containing particles of different sizes, there is an attraction
between the larger particles (the surfactant aggregates) due to
the excluded volume that becomes available to the smaller
particles (the polymer molecules) when the larger particles
approach one another, a wall, or an interface (79,99). The
range of the attraction between the large particles is roughly
the diameter of the small particles, as the small particle con-
centration becomes ‘‘depleted’’ when the gap between the large
particles is too small for the small particles to ﬁt. Depleting
the small particles in the gaps generates an osmotic pressure
between the large particles, leading to an attractive force be-
tween the large particles. In the biological literature, deple-
tion attraction is also known as ‘‘macromolecular crowding’’
(100). The depletion attraction is known to cause colloidal
particles to ﬂocculate in solution (see Fig. 7) (79,99,101) and
concentrate and order at interfaces (99,101–103). The deple-
tion attraction arises for any nonadsorbing polymer in a col-
loidal suspension, and the net attractive force is proportional
to the molecular weight and the polymer concentration. Re-
cent work has shown that the depletion attraction can enhance
FIGURE 11 FFTEM images of 10 mg/ml Infasurf
after adding 5 wt % 10 kDa PEG. (A–D) The PEG
caused the Infasurf aggregates to compact and dehy-
drate; there were no longer vesicle within vesicle struc-
tures, but rather onion-like multilamellar particles. The
small vesicles appear to bind to and fuse with the larger
particles (arrows).
FIGURE 12 FFTEM images of 10 mg/ml Infasurf after
adding 0.25 wt % 250 kDa HA. (A, B) The HA caused
minimal variation in the microstructure of the Infasurf par-
ticles. The open vesicle within a vesicle structure seen in
Fig. 2 is retained. Compare to the onion-like structures in
Fig. 11. Many of the small vesicles remain unfused. The
lower osmotic pressure of the HA is not sufﬁcient to cause
signiﬁcant rearrangement of the Infasurf bilayers.
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the adsorption of large particles (such as surfactant aggre-
gates) to interfaces already covered with smaller particles
(albumin or serum proteins) (17,18,78). In addition to pro-
viding a mechanism of inhibition reversal, macromolecules,
particularly hyaluronan (HA), that naturally exist in the alve-
olar spaces (90) may assist in the normal adsorption of lung
surfactant to the alveolar interface.
CONCLUSIONS
FFTEM of the clinical lung surfactants Survanta, Curosurf,
and Infasurf (FFTEM) shows signiﬁcant differences in the
bilayer organization of the as received materials. The major
difference is the fraction of water within the bilayer aggre-
gates, which increases from Survanta to Curosurf to Infasurf.
Although each clinical surfactant has its own distinct bilayer
organization, freeze-fracture images show that albumin and
polymers do not adsorb to any of the clinical surfactant ag-
gregates. Rather, both albumin and polymers act to dehydrate
the surfactant aggregates by creating an osmotic pressure
between the interior of the aggregate and the exterior. The
aggregates expel any interior pockets of water and form well-
ordered bilayers, with an interlayer spacing that depends on
the osmotic pressure of the polymer or albumin solution. There
is clear evidence of fusion of smaller aggregates to form larger
aggregates, in addition to the ﬂocculation observed via op-
tical microscopy. Small angle x-ray scattering shows that the
d-spacings of Curosurf, Infasurf, and Survanta depend on the
osmotic pressure, consistent with the polymer and albumin
not being able to access the interior of the aggregates (67).
Albumin, polymers, and their mixtures alter the surfactant
aggregate microstructure in the same manner; this implies
that albumin does not inactivate surfactant by alterations in
surfactant microstructure. In addition, the microstructure
alterations of PEG and other polymers do not themselves
reverse surfactant inactivation. This has been shown by
comparing the effects of 5 wt % 10 kDa PEG with 0.25 wt %
250 kDa HA on surfactant microstructure and surfactant
inactivation. These polymer concentrations are sufﬁcient to
reverse inactivation of the clinical surfactants; the lower HA
concentration actually provides more complete inactivation
reversal than does the higher PEG concentration in pulsating
bubble experiments. However, the PEG solution has an os-
motic pressure more than 100 times higher than the HA
solution. FFTEM and small angle x-ray scattering show that
high concentration of PEG necessary to reverse inhibition
signiﬁcantly alters the bilayer organization of the surfactant
aggregates, whereas the lower concentrations of HA do not.
In addition, the bilayer morphology of Survanta is minimally
altered by PEG, whereas Infasurf and Curosurf aggregates
undergo extensive reorganization, yet inactivation reversal
occurs in all of the clinical surfactants. Hence, alternate
mechanisms must be responsible for both inhibition of sur-
factant by surface active proteins and the polymer-induced
inhibition reversal of clinical surfactants.
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